Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RBC, Cisbio Bioassays In Protein Distribution Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

RBC, Cisbio Bioassays In Protein Distribution Pact

Gains rights to co-market and sell RBC's proteins

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Reaction Biology Corp. (RBC) has signed an agreement with Cisbio Bioassays, a biotechnology company that provides services for human in vitro diagnostics and pharmaceutical research, to distribute its epigenetic proteins. RBC manufactures recombinant human epigenetic proteins that modulate genetic function in humans and are being researched as targets for next generation cancer drugs. Cisbio develops and markets assays for drug discovery research and has recently expanded its product offering with solutions to assess epigenetic targets such as methyltransferases. Cisbio will have worldwide rights to co-market and sell RBC’s proteins.
 
“RBC’s portfolio of epigenetic proteins is projected to grow to over 200 this year,” said Dr. Haiching Ma, RBC chief scientific officer. “With more and more international interest, we felt a relationship with an outstanding distributor like Cisbio would bring these proteins to the widest possible client base.”
 
“We have been seeing increasing demand for high quality epigenetic proteins that can be included in the assays that we currently develop,” said Patrick Seguin, vice president of sales and marketing. “RBC’s proteins have met all of our requirements for purity and activity levels, and this agreement represents one step forward in our goal to become a premier provider of epigenetic assays.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics